Vial Announces $67M Series B Led by General Catalyst
Read Vial's feature in the WSJ

Vial Welcomes New Addition, Dr. Joseph Jankovic of Baylor College of Medicine to their Neurology CRO Advisory Board

Dr. Joseph Jankovic of Baylor College of Medicine to their Neurology CRO Advisory Board
Dr. Joseph Jankovic of Baylor College of Medicine to their Neurology CRO Advisory Board

San Francisco, CA. November 9, 2022 — Vial welcomes Dr. Joseph Jankovic as a new Central Nervous System (CNS) advisory board member to their Neurology CRO. Dr. Jankovic is a Professor of Neurology, a Distinguished Chair in Movement Disorders, and the Director of the Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC) at the Baylor College of Medicine.

Dr. Jankovic is a world-renowned expert in the field of Movement Disorders. After completing his medical studies at the University of Arizona College of Medicine and his internship at Baylor College, he received his residency training in Neurology at The Neurological Institute at Columbia University.

Dr. Jankovic has over 40 years of experience, during which he has made significant contributions to describing the pathophysiology and characteristics of and developing treatments for several neurological conditions, including Parkinson’s, cranial cervical dystonia, and tardive dyskinesia. Under Dr. Jankovic’s leadership, the PDCMDC has been recognized as a Center of Excellence by the Parkinson’s Foundation, the Tourette Association of America, and the Huntington’s Disease Society of America. He also has over 1000 peer-reviewed journal publications and edited 55 books.

“Dr. Jankovic’s 40 years of experience is remarkable and will be immensely valuable to enhancing Vial’s Neurology CRO products and services. We are beyond thrilled to have him join our advisory board,” said Simon Burns, Co-Founder and CEO of Vial.

Vial is a tech-enabled CRO providing cutting-edge clinical trial management services that deliver faster, more efficient trials for biotech sponsors. The Vial Neurology CRO distinguishes itself by leveraging digital technology, such as its Vial Technology Platform, which brings together eSourceEDCeTMF, and ePRO, in one connected system to streamline site processes. These best-in-class CRO services will accelerate the development of new therapies and devices for neurology and CNS sponsors and patients.

“It is exciting to see companies like Vial striving to improve the clinical trial space and develop more efficient processes. I’m happy to support new ideas and collaborate on innovations that increase the impact clinical research can have on the lives of patients suffering from neurological diseases and movement disorders,” said Dr. Jankovic on joining Vial’s Neurology CRO advisory board.

Dr. Jankovic’s dedication to the field of neurology, the care of patients, and teaching has been honored through several prestigious awards, including the Great Teacher Award from the National Institutes of Health, Movement Disorders Research Award from the Parkinson’s Disease Foundation, Distinguished Service Awards from the National Parkinson Foundation, Lifetime Achievement Award from Tourette Syndrome Association, and the Master Clinician Lifetime Award from Baylor College of Medicine.

About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. The key to Vial’s tech-enabled platform is Vial’s modern, intuitive Electronic Source and powerful tooling for CRAs that enables considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CROOphthalmology CROOncology CROGastroenterology CRONeurology CRO, Cardiology CRO). Vial is a San Francisco, California-based company with over 125 employees.

Contact Us

Note: If you are looking to participate in a clinical trial, please click here
Name(Required)
By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.